The cost effectiveness of palivizumab: a systematic review of the evidence

References

• Glezen W, Taber L, Frank A, et al. Risk of primary infection and re-infection with respiratory syncytial virus. Am J Dis Child 1986;140:543-546
   PubMedGoogle Scholar
• Parrott R, Kim H, Brandt C, et al. Respiratory syncytial virus in infants and children. Prev Med 1974;3:473-480
   PubMedGoogle Scholar
• Hall C, Weinberg G, Iwane M, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360:588-598
   PubMed Web of Science ®Google Scholar
• Langley J, Wang E, Law B, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 1997;131:113-117
   PubMed Web of Science ®Google Scholar
• Shay D, Holman R, Newman R, et al. Bronchiolitis-associated hospitalizations among US children 1980-1996. JAMA 1999;282:1440-1446
   PubMed Web of Science ®Google Scholar
• Arnold S, Wang E, Law B, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatr Infect Dis J 1999;18:866-869
   PubMed Web of Science ®Google Scholar
• Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009;94:99-103
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al. FLIP-2 study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27:788-793
   PubMed Web of Science ®Google Scholar
• Health Canada, PPHB. Respiratory virus detections/isolations in Canada. http://www.hc-sc.gc.ca/pphb-dgspsp/bid-bmi/dsd-dsm/rvdi-divr/2003pdf/rvdi1103.pdf
   Google Scholar
• Leader S, Kohlase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003;143:S127-132
   PubMed Web of Science ®Google Scholar
• Nokas J, Okiro E, Ngama M, et al. Respiratory syncytial virus infection and disease in infants and young children studied from birth in Kilifi district, Kenya. Clin Infect Dis 2008;46:50-57
   PubMed Web of Science ®Google Scholar
• Rothbarth P, Kimpen J, Roord J, et al. Respiratory syncytial virus infections and preventive options. Ned Tijdschr Geneeskd 2000;144:15-19
   PubMedGoogle Scholar
• Clark S, Beresford M, Subhedar N, et al. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child 2000;83:313-316
   PubMed Web of Science ®Google Scholar
• Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992;121:348-354
   Google Scholar
• IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-537
   Web of Science ®Google Scholar
• Feltes T, Cabalka A, Meissner H, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Cardiac Synagis Study Group. J Pediatr 2003;143:532-540
   Web of Science ®Google Scholar
• Horn S, Smout R. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143:S133-141
   PubMed Web of Science ®Google Scholar
• Willson D, Landrigan C, Horn S, et al. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003;143:S142-149
   PubMed Web of Science ®Google Scholar
• Sampalis J. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143:S150-156
   PubMed Web of Science ®Google Scholar
• Pérez-Yarza E, Moreno A, Lázaro P, et al. The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J 2007;26:733-739
   PubMed Web of Science ®Google Scholar
• Bont L, Steijn M, van Aalderen W, et al. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J. 2004;23:414-417
   PubMed Web of Science ®Google Scholar
• Leidy N, Margolis M, Marcin J, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics 2005;115:1536-1546
   PubMed Web of Science ®Google Scholar
• Sigurs N, Gustafsson P, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171:137-141
   PubMed Web of Science ®Google Scholar
• Stein R, Sherrill D, Morgan W, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541-545
   PubMed Web of Science ®Google Scholar
• McLaurin K, Leader S. Growing impact of RSV hospitalizations among infants in the US, 1197-2002. Pediatric Academic Societies Annual Meeting. Washington, 2005
   Google Scholar
• Miedema C, Kors A, Tjon A, et al. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands. Pediatr Infect Dis J 2001;20:160-163
   PubMed Web of Science ®Google Scholar
• Leader S, Yang H, DeVincenzo J, et al. Time and out of pocket costs associated with respiratory syncytial virus hospitalization of infants. Value Health 2003;6:100-106
   PubMed Web of Science ®Google Scholar
• Samson L. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Paediatr Child Health 2009;14:521-526
   PubMed Web of Science ®Google Scholar
• Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements – modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. 2009;14:521-526
   Google Scholar
• Figueras Aloy J, Quero J, Doménech E, et al. Comité de Estándares de la Sociedad Española de Neonatología. [Recommendations for the prevention of respiratory syncytial virus infection]. An Pediatr (Barc) 2005;63:357-362
   PubMedGoogle Scholar
• Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:238-275
   Google Scholar
• Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care 2005;21:240-245
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manage Care Pharm 2003;9:53-61
   PubMedGoogle Scholar
• Bank of Canada. 10-year currency converter. http://www.bankofcanada.ca/en/rates/exchform.html. Accessed 5 Feb 2010
   Google Scholar
• Bank of Canada. Inflation calculator. http://www.banqueducanada.ca/en/rates/inflation_calc.html. Accessed 5 Feb 2010
   Google Scholar
• ElHassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006;160:1070-1076
   PubMed Web of Science ®Google Scholar
• Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr 2009;35:4
   PubMed Web of Science ®Google Scholar
• Tam DY, Banerji A, Paes BA, et al. The cost-effectiveness of palivizumab for term Inuit infants in the Eastern Canadian Arctic. J Med Econ 2009;12:361-370
   PubMedGoogle Scholar
• Nuijten MJC, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children. Pharmacoeconomics 2007;25:55-71
   PubMed Web of Science ®Google Scholar
• Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ 2009;12:291-300
   PubMedGoogle Scholar
• Resch B, Gusenleitner W, Nuijten MJC, et al. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008;30:749-760
   PubMed Web of Science ®Google Scholar
• Wang D, Cummins C, Bayliss S, et al. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008;12.2008;12:iii, ix-x, 1-86
   Google Scholar
• Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. J Med Econ 2009;12:301-308
   PubMedGoogle Scholar
• Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606-1611
   PubMed Web of Science ®Google Scholar
• Lanctôt KL, Masoud S, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008;24:3223-3237
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010;11:105-115
   PubMed Web of Science ®Google Scholar
• Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;107:419-427
   Google Scholar
• Simpson S, Burls A. A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. Birmingham, UK: Department of Public Health & Epidemiology, University of Birmingham; 2001. Available at: http://www.rep.bham.ac.uk/reports_list.shtml [Last accessed 5 July 2010]
   Google Scholar
• Rodriguez SP, Fariña D. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis. Pediatr Infect Dis J 2008;27:660-661
   PubMed Web of Science ®Google Scholar
• Roeckl-Wiedmann I, Liese JG, Grill E, et al. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:237-244
   PubMed Web of Science ®Google Scholar
• Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier. Arch Pediatr Adolesc Med 2000;154:55-61
   PubMed Web of Science ®Google Scholar
• Vogel AM, McKinlay MJ, Ashton T, et al. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health 2002;38:352-357
   PubMed Web of Science ®Google Scholar
• Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis dues to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol Young 2005;15:251-255
   PubMed Web of Science ®Google Scholar
• Chan PW-K, Abdel-Latif ME-A. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. Acta Paediatrica 2003;92:481-485
   PubMed Web of Science ®Google Scholar
• Fariña D, Rodriguez SP, Bauer G, et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr Infect Dis J 2002;21:287-291
   PubMed Web of Science ®Google Scholar
• Lofland JH, Touch SM, O'Connor JP, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000;22:1357-1369
   PubMed Web of Science ®Google Scholar
• Banerji A, Lanctôt KL, Paes BA, et al. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr Infect Dis J 2009;28:702-706
   PubMed Web of Science ®Google Scholar
• Reeve CA, Whitehall JS, Buetnner PG, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006;42:253-258
   PubMed Web of Science ®Google Scholar
• Sampalis J, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471-480
   PubMed Web of Science ®Google Scholar
• Simões EA, Carbonell-Estrany X, Fullarton JR, et al. and European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP study. Respir Res 2008;9:78
   PubMed Web of Science ®Google Scholar
• Paes BA, Cole M, Latchman A, et al. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada. Curr Med Res Opin 2009;25:2191-296
   PubMed Web of Science ®Google Scholar